Ameriprise Financial Inc. lifted its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,874,214 shares of the biopharmaceutical company’s stock after acquiring an additional 342,580 shares during the quarter. Celgene makes up 0.6% of Ameriprise Financial Inc.’s portfolio, making the stock its 27th biggest position. Ameriprise Financial Inc. owned 1.26% of Celgene worth $1,282,369,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Thompson Davis & CO. Inc. raised its holdings in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene in the first quarter worth $118,000. Motco raised its holdings in Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares in the last quarter. Penserra Capital Management LLC bought a new position in Celgene in the second quarter worth $129,000. Finally, Acropolis Investment Management LLC bought a new position in Celgene in the second quarter worth $144,000. Institutional investors own 80.17% of the company’s stock.
CELG has been the topic of a number of recent research reports. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 target price on the stock. in a research note on Tuesday, August 29th. Royal Bank Of Canada cut their target price on Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a research note on Friday, October 27th. Leerink Swann reissued a “buy” rating and issued a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley cut their target price on Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Celgene in a research note on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Celgene presently has an average rating of “Buy” and a consensus price target of $139.57.
In related news, Director Michael D. Casey sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the sale, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) traded up $0.47 during trading hours on Monday, reaching $102.61. The company’s stock had a trading volume of 5,470,354 shares, compared to its average volume of 4,764,378. The stock has a market capitalization of $81,380.00, a PE ratio of 15.96, a price-to-earnings-growth ratio of 0.79 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the firm posted $1.58 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/ameriprise-financial-inc-purchases-342580-shares-of-celgene-corporation-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.